600285 羚锐制药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)20.96123.46624.64521.27019.268
总资产报酬率 ROA (%)12.17314.26014.76312.46311.436
投入资产回报率 ROIC (%)18.40821.15022.82319.20417.403

边际利润分析
销售毛利率 (%)79.04280.02975.81873.29372.280
营业利润率 (%)26.77623.02623.14619.81917.227
息税前利润/营业总收入 (%)26.42322.69123.10018.66016.338
净利润/营业总收入 (%)23.03819.78620.64017.15615.501

收益指标分析
经营活动净收益/利润总额(%)94.49893.66188.53496.19180.738
价值变动净收益/利润总额(%)6.5704.8524.8583.10512.491
营业外收支净额/利润总额(%)-0.163-0.8882.087-0.500-0.017

偿债能力分析
流动比率 (X)1.2281.0781.3111.3681.465
速动比率 (X)1.0880.8711.0791.1221.181
资产负债率 (%)43.35239.03138.60141.35141.114
带息债务/全部投入资本 (%)8.83511.3673.5667.0437.415
股东权益/带息债务 (%)1,009.184760.9632,650.2781,286.2061,213.334
股东权益/负债合计 (%)129.176154.601158.660141.446142.802
利息保障倍数 (X)-85.173-171.772-42.821-17.595-18.446

营运能力分析
应收账款周转天数 (天)47.23835.02329.70724.69822.119
存货周转天数 (天)164.045203.872191.857194.120197.887